BiotechTube

Imsidolimab + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acneiform Eruptions

Conditions

Acneiform Eruptions

Trial Timeline

May 4, 2021 → Dec 13, 2021

NCT ID
NCT04697069

About Imsidolimab + Placebo

Imsidolimab + Placebo is a phase 2 stage product being developed by Vanda Pharmaceuticals for Acneiform Eruptions. The current trial status is terminated. This product is registered under clinical trial identifier NCT04697069. Target conditions include Acneiform Eruptions.

What happened to similar drugs?

0 of 1 similar drugs in Acneiform Eruptions were approved

Approved (0) Terminated (0) Active (1)
🔄Topical Dapsone 5% Gel + oral antibioticsBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT04856930Phase 2Completed
NCT04856917Phase 2Completed
NCT04697069Phase 2Terminated
NCT04697056Phase 2Terminated
NCT03633396Phase 2Completed

Competing Products

2 competing products in Acneiform Eruptions

See all competitors
ProductCompanyStageHype Score
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 PlaceboHoth TherapeuticsPhase 2
32
Topical Dapsone 5% Gel + oral antibioticsBristol Myers SquibbPhase 3
40